<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02160574</url>
  </required_header>
  <id_info>
    <org_study_id>130820-302 (ZX-ZP-0017)</org_study_id>
    <nct_id>NCT02160574</nct_id>
  </id_info>
  <brief_title>Safety Study to Evaluate the Cumulative Irritation Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA</brief_title>
  <official_title>A 21-Day Evaluation of the Cumulative Irritation Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zurex Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zurex Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a safety study to determine the cumulative skin irritation potential of ZuraPrep™ and
      ZuraPrep™ without Isopropyl Alcohol after repetitive patch applications to skin of human
      subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This cumulative irritation evaluation is designed to determine the skin irritation potential
      of ZuraPrep™ and ZuraPrep™ without Isopropyl Alcohol (IPA) after repetitive patch application
      to skin of healthy human subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Scoring Scale (0-7) for Visual Evaluation of Skin Condition</measure>
    <time_frame>0-21 days post dose</time_frame>
    <description>Results from skin scores of ZuraPrep and ZuraPrep without IPA will be compared statistically, and both will be compared to the Positive Control (0.1% Sodium Lauryl Sulfate).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scoring Scale (0-7) for Visual Evaluation of Skin Condition</measure>
    <time_frame>0-21 days post dose</time_frame>
    <description>The degree of skin irritation caused by the Reference Product (ChloraPrep) and the Negative Control (0.9% Physiological Saline) will be graded.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Surgical Site Infection</condition>
  <arm_group>
    <arm_group_label>ZuraPrep</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ZuraPrep will be compared statistically to ZuraPrep without IPA and both to the Positive Control (0.1% Sodium Lauryl Sulfate). The degree of skin irritation caused by the Reference Product (ChloraPrep) and the Negative Control (0.9% Physiological Saline) will be graded.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ChloraPrep</intervention_name>
    <description>The degree of skin irritation caused by ChloraPrep will be graded and compared to ZuraPrep and ZuraPrep without IPA.</description>
    <arm_group_label>ZuraPrep</arm_group_label>
    <other_name>Reference Product</other_name>
    <other_name>2% Chlorhexidine Gluconate and 70% IPA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.1% Sodium Lauryl Sulfate</intervention_name>
    <description>The degree of skin irritation caused by 0.1% Sodium Lauryl Sulfate will be graded and compared to ZuraPrep and ZuraPrep without IPA.</description>
    <arm_group_label>ZuraPrep</arm_group_label>
    <other_name>Positive Control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% Physiological Saline</intervention_name>
    <description>The degree of skin irritation caused by 0.9% Physiological Saline will be graded and compared to ZuraPrep and ZuraPrep without IPA.</description>
    <arm_group_label>ZuraPrep</arm_group_label>
    <other_name>Negative Control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ZuraPrep without IPA</intervention_name>
    <description>Results from exposure to ZuraPrep will be compared statistically those from exposure to ZuraPrep without IPA</description>
    <arm_group_label>ZuraPrep</arm_group_label>
    <other_name>ZuraPrep without Isopropol Alcohol (IPA)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects may be of either sex, at least 18 years of age and of any race

          -  Subjects must be free of tattoos, sunburn, dermatoses, cuts, lesions or other
             disorders of the skin of the back.

          -  Subjects must be in good general health

        Exclusion Criteria:

          -  Known allergies to latex, metals, tape and/or adhesives, soap, citric acid, methylene
             blue, methylparaben, propylparaben, chlorhexidine gluconate, isopropyl alcohol, and
             sodium lauryl sulfate.

          -  Exposure of the back region to antimicrobial agents, medicated soaps, medicated
             shampoos, medicated lotions, strong detergents, sun-tanning, use of tanning beds, or
             swimming or soaking in pools or hot tubs, in the 7 days prior to, or during the 3-week
             test period.

          -  Use of topical or systemic corticosteroid, antihistamine, or anti-inflammatory
             medications in the 7 days prior to, or during the 3-week test period.

          -  Current or recent severe illness such as asthma, diabetes, hepatitis, organ
             transplant, mitral valve prolapse, congenital heart disease, internal prostheses, or
             any immunocompromised condition such as AIDS or HIV positive.

          -  Pregnancy, plans to become pregnant, breast-feeding

          -  Any active skin rash or breaks in the skin of the back

          -  Any sunburn or tattoos on the skin of the back

          -  Current active skin disease or inflammatory skin condition including contact
             dermatitis

          -  Participation in a clinical study in the past 7 days or current participation in
             another clinical study

          -  Any medical condition or use of any medications that, in the opinion of the Principal
             Investigator, would preclude participation

          -  Unwillingness to fulfill the performance requirements of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esther Campbell</last_name>
    <role>Principal Investigator</role>
    <affiliation>BioScience Laboratories, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BioScience Laboratories</name>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <zip>59718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2014</study_first_submitted>
  <study_first_submitted_qc>June 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2014</study_first_posted>
  <last_update_submitted>October 24, 2014</last_update_submitted>
  <last_update_submitted_qc>October 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Surgical Wound Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

